To assess the relationship between cardiovascular magnetic resonance (CMR) parameters and both spontaneous ventricular tachycardia (VT) and risk of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) patients.
Introduction
Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in the young. 1, 2 Most individuals with HCM are asymptomatic and the first manifestation may be SCD. 3 -5 The only effective preventive treatment is the implantable cardioverter-defibrillator (ICD). 6 -8 However, given the relatively low mortality of patients with HCM, 9 this therapy is not appropriate for all patients. Furthermore, ICD implantation may be associated with complications and low quality of life. 10 Therefore, a major challenge in the management of HCM patients is to select those who are at a higher risk for clinical ventricular arrhythmias or SCD and, therefore, may benefit from prophylactic ICD implantation. Cardiac magnetic resonance (CMR) is a useful diagnostic tool that can accurately diagnose and characterize HCM patients. 11 Aim of the present study was to assess the relationship between CMR parameters including both spontaneous ventricular tachycardia (VT) and risk of SCD in HCM patients.
Methods Patients
This study included consecutive, non-selected patients with HCM who were referred for CMR exam as part of their routine evaluation in our Institution from December 2004 to April 2008. CMR data and endpoint definition were prospective, whereas clinical data were collected retrospectively from the medical charts. Thus, the study should be considered a retrospective study. Diagnosis of HCM was based on the echocardiographic demonstration of a left ventricular wall thickness (LVWT) 15 mm in the absence of a different cardiac or systemic disease that could account for the hypertrophy. The assessment of the risk status for SCD was based on both a comprehensive clinical evaluation including medical history as well as treadmill test, Holter electrocardiogram (ECG), and a genetic evaluation performed at the same time of CMR study. Exercise and Holter ECG were usually obtained during the same clinical visit of the CMR evaluation (we decided to include patients who did not undergo these tests at the same time if tests performed within 12 months from CMR were available).
Overall, 120 patients underwent CMR and were initially included in the study. However, two patients had a CMR exam of poor quality because of difficult ECG synchronization owing to atrial fibrillation and two patients had a genetic analysis that disclosed a different disease (Fabry disease and Danon disease, respectively); thus, these four patients were excluded. Furthermore, eight patients had incomplete clinical data and were also excluded from the analysis. This process leads us to include 108 patients in the final cohort. We decided not to exclude patients who did not give their informed consent to genetic analysis or for whom this analysis was not completed. Following the policy of our Ethics Committee for observational studies, patients signed written informed consent for CMR examination, for genetic analysis, and for treatment of sensible clinical data.
Genetic evaluation
Ninety-eight patients (91% of the total cohort) underwent genetic testing. The analysis of disease genes was performed on DNA obtained from peripheral blood samples (Maxwell 16, automated nucleic acid extraction work station), after pre-test genetic counselling. We used denaturing high-performance liquid chromatography for heteroduplex detection and direct bidirectional sequencing of the heteroduplex amplicons with the BigDye Terminator Cycle sequencing kit V 3.1 (Applied Biosystems) on the ABI 3130Xl Genetic Analyzer, following the manufacturer's directions. Direct automated sequencing was performed when parents were unavailable for screening in order to exclude rare cases of recessive inheritance and for the analysis of mitochondrial DNA (mtDNA). Sequences were analysed with Sequencer 4.0 software. Results were compared with those obtained in 200 healthy individuals with normal ECGs and no evidence of cardiac disease. The genetic analysis included a screening of sarcomeric genes (MYH7, MYBPC3, TNNT2, TNNI3, TNNC, alphaTPM, TCAP, ACTC,  MYOZ2, MYL1, MYL2, MYL3 ) and mtDNA. Genes that cause HCM phenocopies (GLA, LAMP2, PRKAG) were evaluated in all 98 patients and were negative (two positive cases were excluded from the original cohort). Among these 98 patients, a mutation was found in 51 patients, while search for other mutations is still ongoing in the other 47 patients. According to the ACC/ESC Clinical Expert Consensus Document on HCM, 1 we considered R403Q, R453C, G716R, and R719W mutations in the b-myosin heavy chain (MYH7) and R92W mutation in the cardiac troponin T gene (TNNT2), as high-risk mutations.
Cardiac magnetic resonance
CMR was performed on 1.5 T scanner (Siemens Symphony, Erlangen, Germany). Cine images with steady-state free-precession (trueFISP; slice thickness 8 mm) were acquired in three long-axis planes and contiguous short-axis slices (no gap) from the atrioventricular ring to the apex. A intravenous bolus of 0.2 mmol/kg gadolinium-DTPA (Magnevist, Schering, Berlin, Germany) was then given and late gadolinium images were acquired in the same planes after 10 min, with breath-hold segmented inversion-recovery sequence (inversion time 240 -300 ms). Both global LV function and segmental wall thickness were analysed using commercially available software by manual tracing of endocardial and epicardial contours (Argus, Siemens Medical Solutions, Erlangen, Germany). The following parameters (normalized to body surface area) were calculated by planimetry of short-axis cine images: LV end-diastolic volume index (LVEDVI; mL/m 2 ), LV end-systolic ). End-diastolic wall thickness was measured in short axis for 16/17 segments and in long axis for the apex. All 17 values were averaged to obtain the mean end-diastolic thickness [MEDT (mm), see Figure 1 ].
The overall amount of LV delayed contrast enhancement (DCE) was semi-quantitatively estimated using a visual score system. To each of the 17 segments, 0 points were attributed in the absence of DCE, 1, 2, and 3 points in the presence of DCE involvement ,25%, between 25 and 50%, or .50% of the segment area, respectively. Preliminary to this study we have performed blinded analyses on duplicate and found excellent interobserver and intraobserver concordance on DCE score. Each individual segment score was then added to obtain a total DCE score for each patient ( Figure 2 ). All CMR analyses were performed blindly, without the knowledge of the clinical characteristics of patients.
Risk definition of sudden cardiac death
According to the ACC/ESC Clinical Expert Consensus Document on HCM, 1 we considered at increased risk for SCD (Group R) patients with at least one of the following: (i) prior cardiac arrest or spontaneously occurring and sustained VT; (ii) family history of a premature HCM-related SCD; (iii) identification of a high-risk mutant gene; (iv) unexplained syncope; (v) abnormal blood pressure response during treadmill ECG test; (vi) non-sustained VT on Holter ECG (of three beats or more and of at least 120 b.p.m.); (vii) extreme LV hypertrophy (maximum LVWT of 30 mm or more). We divided Group R patients in two subgroups: a 'high-risk group' (HR) including patients who experienced a prior cardiac arrest or sustained VT and patients who had at least two of the other risk factors, in whom there is a compelling indication for ICD implantation 1 and an 'intermediate risk group' (IR) including patients who had only one of the other risk factors, in whom ICD implantation is considered reasonable based on current guidelines. 12 Patients without any of these risk factors were considered to be at low risk for SCD (group LR).
Statistical analysis
Our target sample size of approximately 110 patients was chosen for two reasons. First, we considered that this sample size would allow us to have approximately 30 -50 endpoints (VT or SCD risk status), and shown. The top left image shows a case of absence of DCE (0 points), the top right image a case of DCE involvement ,25% (1 point), the bottom left image a case of DCE involvement 25-50% (2 points), the bottom right image a case of DCE involvement .50% (3 points). Each individual segment score was then added to obtain a total DCE score.
Usefulness of cardiac magnetic resonance in patients with HCM thus would allow us to test the independent predictive role for up to three to five variables in the multivariable model. 13 Secondly, we wanted to have a population that would be at least double when compared with that of the sole published article at the time of study conception, namely that of Moon et al., 14 which included 53 selected HCM patients and could not perform multivariable analysis. Data are expressed as mean + SD for normally distributed data and as median (interquartile range) for non-normal data. The Student's t-test or one-way analysis of variance (ANOVA) were employed, as appropriate, for comparison of normally distributed data. Positively skewed data were normalized using natural log transformation. 15 Welch's ANOVA was used to accommodate unequal variance in the setting of normal data. 15 The x 2 test was utilized to compare categorical variables expressed. Interobserver and intraobserver agreement was assessed with the Cohen's kappa statistics.
Predictors of clinical arrhythmias and SCD risk were assessed with logistic regression analysis. 16 The linearity assumption in the model was assessed and satisfied for all continuous variables tested using the Box-Tidwell test. All CMR variables as well as age and gender were evaluated as potential univariate predictor of the presence of clinical arrhythmias (cardiac arrest, sustained VT, and non-sustained VT) and of SCD risk (Group LR vs. R). The final model included all univariate predictors with P 0.05 [DCE score and LVMI for clinical arrhythmias; DCE score, MEDT, LVMI, and maximal LV wall thickness (MaxLVWT) for SCD risk].
For a better characterization of the ordinal nature of the three risk groups classification (LR vs. IR vs. HR), we use ANOVA tests of linearity for those comparisons between all the three risk groups that showed a significant difference (i.e. LVMI, MEDT, MaxLVWT, and DCE score). Post hoc comparisons were performed using Bonferroni or Tamhane's T2 adjustment for multiple pair-wise comparisons as appropriate at a 0.05 significance level.
Since the predictive value of the morphological CMR parameters (MEDT, LVMI, maximum LVWT) was inherently biased by the presence of a maximum LVWT 30 mm in the risk definition of SCD, we created a new classification of risk excluding the criterion of LVWT 30 mm. Patients with and without at least one risk factor different from LVWT 30 were thus assigned to the new R and new LR groups, respectively.
Finally, the ability of MEDT, LVMI, MaxLVWT, and DCE score to discriminate LR vs. HR patients was assessed using the area under the receiver-operating characteristic (ROC) curve (c-index) with 95% confidence interval (CI). All comparisons were two-tailed. P , 0.05 was considered to be statistically significant.
Results
Principal characteristics of the study population are summarized in Table 1 .
The distribution of mutated proteins in the 98 patients who underwent genetic analysis is described in Table 2 . Notably, only one patient had a high-risk mutation (R453C in the b-myosin heavy chain gene). Reproducibility data of DCE scoring system were assessed in 255 segments and resulted in an intraobserver (C.R.) kappa value of 0.86 (P , 0.0001) and interobserver (C.R., A.V.) kappa value of 0.82 (P , 0.0001), indicating almost perfect agreement. 17 The main clinical and CMR characteristics for patients with clinical ventricular arrhythmias [VT, ventricular fibrillation (VF), and cardiac arrest; n ¼ 33] compared with those of patients without clinical arrhythmias (n ¼ 75) are shown in Table 3 . Among patients with clinical arrhythmias, DCE score was higher [8 (2-13) vs. 11 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ; P ¼ 0.01], whereas the difference in maximal LV thickness did not reach statistical significance. While DCE score and LVMI were both univariate predictors for clinical arrhythmia, in the multivariable model only DCE score proved to be an independent predictor (P ¼ 0.004; see Table 4 ).
On the basis of the presence of risk factors, 51 patients (47%) were attributed to the R group and 57 patients (53%) to the LR group. The former group included 31 and 20 patients at intermediate and high-risk, respectively. The mean age and gender 12 (11) LVOTG 30 mmHg, n (%) 16 (15) Ap. HCM, n (%) 6 (6)
Prevalence of risk factors CA or sVT, n (%) 7 (6) Fam. SCD, n (%) 9 (8) HR mut., n (%) 1 (1) Syncope, n (%)
3 (3) Abn. exer. BP, n (%) 4 (4) NSVT, n (%) 33 (31) MaxLVWT 30 mm, n (%)
16 (15) BSA, body surface area calculated with the Du Bois formula (m 
Mut. ident., mutation identified; MYH7, myosin heavy chain-b (MHC-b) isoform; MYBPC3, cardiac myosin-binding protein C; tCAP, titin-cap; TNNI3, cardiac troponin I3; TNNT2, cardiac troponin T2; mtDNA, mitochondrial DNA.
distribution was similar among the three groups as shown in Table 5 which also indicates the main results of CMR in the different groups. LVMI was significantly greater in Group R compared with Group LR [85 (76-121) vs. 77 (64-99); P ¼ 0.002]. As expected, the maximum wall thickness differed among the groups. Interestingly, highly significant differences (P , 0.0001) were also found in the MEDT, comparing both Group LR (10.5 + 1.9 mm) and Group R (12.5 + 3.6 mm) as well as the three groups: LR, IR (11.5 + 2.3 mm), and HR (14.5 + 4.6 mm). LVEDV and LVEF did not differ among the groups.
Prevalence of DCE was very common both between LR and R patients (81% and 92%, respectively; P ¼ 0.13). However, the use of the scoring system disclosed a marked and significant difference among the three groups, ranging from a median score of 6 among low-risk patients to a median score of 13.5 among high-risk patients. Moreover, in the multivariable analysis with risk status as dependent variable, DCE score and MaxLVWT were the only independent predictors of Group R (respectively, P ¼ 0.019 and P ¼ 0.004; see Table 6 ).
For the sake of completeness, we have repeated the analysis excluding the two patients with mtDNA mutations obtaining nearly identical results; in the multivariable model, DCE score remains to be a significant predictor of clinical arrhythmia and of SCD risk (P-values of 0.007 and 0.003, respectively).
As specified in the Methods section, to reduce the bias owing to the presence of a maximum LVWT 30 mm in the risk definition of SCD, we compared the characteristics of patients in the new R and new LR Group. These two groups included 41 and 67 patients, respectively.
LVWT 30 was equally distributed in the new R and new LR groups (x 2 ¼ 1.04, df ¼ 1; P ¼ 0.31). On the other hand, similar to the original risk groups, MEDT, LVMI, and MaxLVWT differed significantly (P ¼ 0.009, 0.025, and 0.013, respectively) also between new R and new LR groups. Of special interest, even in the subgroup of patients with at least one segment of 30 mm or more (LVWT 30), MEDT maintained its ability to discriminate between new R vs. new LR patients (18.3 + 3.9 vs. 13.7 + 3.1; P ¼ 0.021) and between arrhythmic vs. non-arrhythmic patients (18.6 + 4.6 vs. 14.4 + 3.2; P ¼ 0.047). Finally, given the importance of identifying HR patients, we generated ROC curves to assess the capability of the CMR parameters to discriminate HR vs. LR groups. The best discriminating capacity was present in MEDT followed by LVMI, MaxLVWT, and DCE score. Area under curve was 0.86 (95% CI 0.74 -0.98; P , 0.0001) for MEDT, 0.83 (95% CI 0.70 -0.96; P , 0.0001) for LVMI, 0.82 (95% CI 0.69-0.94; P , 0.0001) for MaxLVWT and 0.71 (95% CI 0.55-0.86; P ¼ 0.012) for DCE score (Figure 3) . P-value* P-value # P-value** P-value*** P-value**** Data are presented as mean + standard deviation, except for DCE present and male gender (presented as proportion) and DCE score and LVMI presented as median (interquartile range). LVMI, left ventricular mass index; MaxLVWT, maximal left ventricular wall thickness; MEDT, mean end-diastolic thickness; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; DCE present, proportion of patients with DCE present; DCE score, delayed contrast enhancement score. *P-value between the three groups. **P-value LR vs. IR. ***P-value LR vs. HR. ****P-value IR vs. HR. For definition of risk groups see text. LVMI and DCE score were analysed with parametric tests after normalization with log-transformation. 14 in a preliminary study of highly selected HCM patients.
The present study was performed in a larger series of unselected consecutive patients, thus allowing conclusions which may be more easily transferred to the overall population of patients with HCM. Furthermore, our data suggest that the extent of DCE may also be increased in patients at intermediate risk (i.e. patients with a single minor risk factor for SCD). In addition to DCE, the only other independent predictor of SCD risk in the multivariable model was MaxLVWT. This is a simple parameter to estimate with CMR at variance with what may occur with echocardiography particularly in the anterolateral LV free wall. 11 It should be pointed out that the fact that the presence of LVWT 30 mm was a criterion to be assigned to the risk group, certainly increased the likelihood that MaxLVWT would be found to significantly predict risk. Use of the new R group classification (excluding LVWT 30 mm as a risk criterion) disclosed the predictive role of MEDT and LVMI. These two variables were also shown to have the best discriminating capacity between low-risk and highrisk. These findings raise the possibility that MEDT and LVMI could add prognostic value to the LVWT 30 mm criterion. Of course, this hypothesis should be validated prospectively.
Overall, the findings of the present study are in agreement with the concept that DCE, representing an abnormal myocardial substrate, may have a role in increasing the risk for ventricular arrhythmias and SCD. The study also suggests that a semi-quantitative estimation of DCE may help in the identification of patients at risk and thus contribute to the choice of prophylactic ICD implantation in selected or borderline cases.
In our study two patients have mtDNA mutations. These patients challenge the concept of HCM as a sarcomeric disease. However, they are presently considered HCM patients worldwide. 21 -23 Moreover, the conclusions of the study were not affected by the exclusion of these two patients. Thus, we decided not to exclude them from the analysis. Our study has important limitations. First, we used a surrogate of SCD for risk stratification. Although this approach is in agreement with previous studies 14 and risk status was established very accurately and included genetic screening for high-risk mutations, we are aware of the marked difference between risk of SCD and actual occurrence of SCD. However, given the event rate expected in a general population of HCM patients 9 of 1% per year, an overall follow-up of 3000-5000 patients-year would be required to obtain the same number of endpoints considered in this study (33 for clinical arrhythmia and 48 for risk of SCD). Smaller number of events would not afford sufficient power to assess an adequate number of multivariable predictors. 13 An alternate approach would be to consider at high-risk patients with either a history of cardiac arrest or an appropriate ICD intervention. Although this approach may be useful to assess the association of SCD risk with other predictors, it is unfortunately not applicable in the case of CMR.
A second potential limitation was the use of a semi-quantitative rather than quantitative estimate of the extent of DCE. However, all measures were performed blindly thus excluding the potential for bias in the quantification of DCE. Quantitative analysis is limited by the absence of any consensus on the optimal cut-off value for the definition of DCE among patients with ischaemic heart disease, 24 by the absence of any data on this aspect in patients with HCM, and by the bizarre pattern of DCE distribution in these latter patients that causes quantitative automatic analysis unreliable and quantitative manual analysis cumbersome. Indeed, we have tried to apply the automatic method at the beginning of the study with unsatisfactory results owing to the need of a considerable amount of subsequent manual correction and to low interobserver reproducibility. On the other hand, the present method has a high reproducibility, is faster and may be more easily applied in daily practice.
Conclusions
In patients with HCM, several CMR parameters are associated with increased risk features for SCD. A semi-quantitative index of DCE is a significant multivariable predictor of both clinical VT and of risk for SCD. These findings require confirmation in large prospective studies but they may already contribute to risk stratification and potentially to clinical decision-making in borderline or controversial cases.
